Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin.

ABSTRACT:

Background

Breast cancer often metastasizes into bone and leads to osteolytic lesions. The underlying mechanisms, however, are complex and not fully understood. Syndecan-1 is a proteoglycan that has various functions relevant for tumor progression including cell-cell communication and cell-matrix interactions. Moreover, its two glycosaminoglycan-binding sites suggest that it may interfere with glycoproteins such as osteoprotegerin, a potent inhibitor of osteoclastogenesis. Thus, we hypothesize that tumor-derived syndecan-1 alters osteoclast biology by modulating osteoprotegerin.

Methods

Syndecan-1 expression was down-regulated via siRNA and the cell fate of the breast cancer cell lines MCF-7, T-47D, and MDA-MB-231 was investigated. Furthermore, we determined the regulation o

SUBMITTER: Benad-Mehner P 

PROVIDER: S-EPMC4723417 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature